Rezera, a 5AM Ventures portfolio company, announced positive topline results from RESOLVE-1 Phase 2 trial of ruvonoflast (NLRP3 inhibitor) meeting its primary inflammation endpoint, with plans to initiate Phase 3 in PAD in H1 2027.
Clinical-stage biotechnology company developing oral NLRP3 inhibitors to reduce chronic inflammation in cardiovascular and neurological diseases
Clinical-stage biotechnology company developing oral NLRP3 inhibitors to reduce chronic inflammation in cardiovascular and neurological diseases. Its lead candidate, ruvonoflast, is being advanced for peripheral artery disease, while trabzanoflast is designed for neuroinflammatory diseases.